Heminevrin

Heminevrin is an oral tablet containing the sedative‑hypnotic clomethiazole. It is marketed in the European Union and is prescribed as a prescription‑only medication. The tablet formulation delivers clomethiazole, a positive allosteric modulator of the GABA‑A receptor, used to manage central nervous system depression in specific clinical situations. It is typically administered under medical supervision for conditions such as alcohol withdrawal, procedural sedation, and short‑term treatment of insomnia.

Heminevrin is indicated for several central nervous system conditions where sedation or withdrawal management is required.

- Management of alcohol withdrawal syndrome, particularly to reduce agitation and risk of seizures. - Short‑term sedation for diagnostic or therapeutic procedures requiring moderate depth of anesthesia. - Treatment of acute insomnia when other therapies are unsuitable or ineffective. - Adjunctive therapy for severe anxiety or agitation in a hospital setting under close monitoring.

The pharmacological activity of clomethiazole can produce a range of adverse effects, which are generally categorized by frequency and severity.

Common: - Drowsiness or excessive sleepiness, which may impair daily activities. - Dizziness or a light‑headed sensation, often occurring shortly after dosing. - Headache of mild to moderate intensity. - Nausea, occasional vomiting, or mild gastrointestinal discomfort.

Serious: - Respiratory depression, potentially life‑threatening, particularly when used with alcohol or opioids. - Severe hypotension or cardiovascular collapse requiring immediate medical attention. - Hepatic dysfunction, indicated by jaundice, dark urine, or markedly elevated liver enzymes.

Because clomethiazole depresses central nervous system activity, several precautions should be observed before and during therapy.

- Assess patient history for respiratory disorders, such as asthma or chronic obstructive pulmonary disease. - Evaluate liver function, as clomethiazole is metabolized hepatically and may accumulate in hepatic impairment. - Use caution in elderly patients who are more susceptible to sedation and falls. - Avoid abrupt discontinuation to reduce risk of rebound agitation or withdrawal symptoms. - Monitor vital signs, especially respiratory rate and blood pressure, during initial dosing. - Consider alternative agents in pregnant or breastfeeding individuals due to limited safety data.

Clomethiazole can interact with other medications that affect the central nervous system or hepatic metabolism.

Avoid: - Alcohol or other CNS depressants (e.g., benzodiazepines, opioids) due to additive respiratory depression. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) which can increase clomethiazole plasma levels. - Other sedative‑hypnotics or antihistamines that may potentiate drowsiness.

Use with caution: - CNS stimulants (e.g., caffeine, amphetamines) which may counteract sedative effects. - Anticonvulsants that are metabolized by the liver, requiring dose adjustments. - Antidepressants, particularly SSRIs, where combined use may increase sedation.